This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline

Acquiring Scioderm gives Amicus another late-stage orphan disease drug expected to have pivotal trial data in the first half of next year.

Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews

Approving both the Biomarin and Sarepta drugs for Duchenne muscular dystrophy is the most politically expedient decision the FDA can make.

An Inside Look at Biotech Investor Pros Dealing With Market Meltdown

Last night, I exchanged emails with a number of investors who run dedicated health care funds. I wanted to know how they navigated Monday's market selloff.

Biotech Stocks Recover From Early-Morning Flash Crash

The iShares Nasdaq Biotechnology Index (IBB), the most closely followed biotech sector index, is down less than 1% after a deep plunge at Monday's open.

Northwest Bio Forced to Temporarily Halt Enrollment of Brain Tumor Vaccine Study (Update)

Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.

Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio

Biotech columnist Adam Feuerstein answers readers' questions about health care.

MannKind Financial Woes Escalate on Failed Debt Settlement

The slow commercial launch of Afrezza, MannKind's inhaled mealtime insulin, continues to be the root cause of the company's balance-sheet woes.

Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief

Speculative biotech stocks that were huge winners for healthcare investors earlier this year are now down significantly from their 52-week highs.

Biotech Stock Mailbag: Controversial Stocks Revisited

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Seven Reasons to Love Biomarin's Duchenne Drug Falls One Short

RBC Capital analyst Michael Yee offers seven reasons why Biomarin Pharmaceuticals will secure U.S. approval for drisapersen to treat Duchenne muscular dystrophy, a rare, genetic muscle-wasting disease.

Page 1 of 340
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs